Staff

Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19

Kopin Corporation and HMDmd Enter Development Agreement with Major US Medical Technology Company to Develop Wearable Display System for Surgeons

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Kopin® Corporation (NASDAQ: KOPN), a leading developer of high-resolution microdisplays, display subassemblies and head-mounted display systems, and HMDmd,...

error: Content is protected !!